Replies to post #20955 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

DCMAN, Jade Capital

You Said

"Jade was an interesting story early on, but I don't think they amount to much in the grand scheme of things."


That could be true about Jade. One of the posters here knows a lot about Jade I understand. Too bad the person who started this board is not around? Happy Easter DC...Wolf




dcspka Sunday, 04/20/14 02:15:07 PM
Re: vester_guy post# 20954
Post # of 20955
Vester_guy, you said: "This filing [Jade Capital Group] must be very important to cause someone to start this RPC/RXPC board..What do you say?"

I say "this someone" may have been a player early on, but has been left behind and forgotten in the process. Misery likes company, and he/she is making sure they have some.

Bingo. Ding, ding, ding!

Jade was an interesting story early on, but I don't think they amount to much in the grand scheme of things. Maybe their name will be heard again along side of Provista regarding a financial deal/ agreement of some sort- but only as a secondary player, we'll see.

[lakeshore555]

Jade amounts to NOTHING as far as Radient is concerned.

Jade left Radient and took the equity with them. The reason RPC became RXPC is because the SEC forced the company to admit their Jade holding was worthless and Radient therefore had a shareholder deficit, not shareholder equity.

Today, Radient has no equity and their only remaining asset will be worthless in five weeks when the patent expires. RXPC is about the worst possible "investment" a person could make. I challenge anyone to find a stock that would be a poorer investment.

[guardiangel]

DCMAN Jade Pharma

This is why Jade is out of the picture DCMAN..They were worthless in my opinion..Mac and the gang dropped Jade for Onko-Sure..Wolf

Radient Pharmaceuticals: New Name, New Focus


By By Ed Rabinowitz | May 19, 2010
- See more at: http://www.hcplive.com/publications/obtn/2010/february_2010/radient_pharmaceuticals#sthash.5q8yAgDF.dpuf

"That changed on September 18, 2009, when the firm refocused its core business strategy on the international commercialization of its Onko-Sure In Vitro Diagnostic (IVD) Cancer Test Kits and, to a lesser extent, Elleuxe skin care products."